Our Centre for Therapeutics Discovery
offers world-class facilities
Centre staff
CTD staff are based in our Mill Hill labs. They include:
• 12 medicinal chemists
• 2 computational chemists
• 2 analytical and in-vitro DMPK specialists
• 17 assay development, screening scientists and cell pharmacologists
• 10 antibody scientists (forming the Therapeutic Antibody Group)
Compound collection
• 100,000 compound Diversity set
• 14,000 compound alpha helix mimetic set
• 7,000 compound kinase set
• 4000 natural products
• 3000 pharmacologically active tool set
• 1000 fragment screening set
Useful machinery
• Analytical LC-MS/MS for compound characterisation and ADME profiling
• ClonePix for screening and selection of cell line clones when generating assay cell lines, research antibodies or biotherapeutics
• Pharma level standard of liquid handling and screening robotic platforms
News feed
MRCT are collaborating with the University of Bristol to develop orally available small molecule TrkA antagonists for treatment of chronic intractable pain.
MRC Technology’s Therapeutic Antibody Group and The University of Aberdeen work together on project to develop therapeutic against a novel cancer target, soluble CTLA-4.
Aptuscan, a spin out company based on research carried out at the MRC Cancer Cell Unit, has been acquired by Avacta, an AIM-listed biotechnology company.
MRC Technology announced today that they have entered into an agreement with the Association for International Cancer Research (AICR) to assist in the oversight and management of intellectual property (IP) arising from AICR-funded projects.